hologic , inc . notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) the acquisition also provides for up to two annual earn out payments not to exceed $ 15000 in the aggregate based on biolucent 2019s achievement of certain revenue targets . the company has considered the provision of eitf issue no . 95-8 , accounting for contingent consideration paid to the shareholders of and acquired enterprise in a purchase business combination , and concluded that this contingent consideration will represent additional purchase price . as a result , goodwill will be increased by the amount of the additional consideration , if any , when it becomes due and payable . the allocation of the purchase price is based upon preliminary estimates of the fair value of assets acquired and liabilities assumed as of september 18 , 2007 . the company is in the process of gathering information to finalize its valuation of certain assets and liabilities . the purchase price allocation will be finalized once the company has all necessary information to complete its estimate , but generally no later than one year from the date of acquisition . the components and initial allocation of the purchase price , consists of the following approximate amounts: .

net tangible assets acquired as of september 18 2007 | $ 2800
developed technology and know how | 12300
customer relationship | 17000
trade name | 2800
deferred income tax liabilities net | -9500 ( 9500 )
goodwill | 47800
estimated purchase price | $ 73200

as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued . it was determined that only customer relationship , trade name and developed technology and know how had separately identifiable values . the fair value of these intangible assets was determined through the application of the income approach . customer relationship represents a large customer base that are expected to purchase this disposable product on a regular basis . trade name represents the biolucent product names that the company intends to continue to use . developed technology and know how represents currently marketable purchased products that the company continues to sell as well as utilize to enhance and incorporate into the company 2019s existing products . the deferred income tax liability relates to the tax effect of acquired identifiable intangible assets , and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes partially offset by acquired net operating loss carryforwards of approximately $ 2400 . fiscal 2006 acquisitions : on may 2 , 2006 , the company acquired 100% ( 100 % ) of the outstanding voting stock of aeg elektrofotografie gmbh and its group of related companies ( aeg ) . the results of operations for aeg have been included in the company 2019s consolidated financial statements from the date of acquisition as part of its other business segment . the company has concluded that the acquisition of aeg does not represent a material business combination and therefore no pro forma financial information has been provided herein . aeg specializes in the manufacture of photoconductor materials for use in a variety of electro photographic applications including for the coating of the company 2019s digital detectors . the acquisition of aeg allows the company to have control over a critical step in its detector manufacturing process 2014to more efficiently manage .

Question: what is the total value of intangible asset taken into account when setting up the estimated purchase price?
Program: add(12300, 17000), add(#0, 2800), add(#1, 47800)
Answer: 79900.0